solute carrier family 17 member 1Genealiases: NAPI-1 · NPT-1 · NPT1
Q-omics provides the consensus-scored SLC17A1 profile across patient tissues and cancer cell-line models. SLC17A1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC17A1 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, SLC17A1 RNA expression shows 8,978 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where SLC17A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC17A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC17A1 survival associations across molecular data types. SLC17A1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC17A1 RNA expression–survival associations across cancer types. High SLC17A1 expression shows unfavorable associations in UVM, BLCA, SCLC and READ, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC17A1 RNA expression.
This table summarizes SLC17A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 3. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC17A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC17A1 shows lower tumor expression in COAD, KICH, LUSC, KIRP and CHOL. The COAD box plot shows higher SLC17A1 RNA expression in normal versus tumor tissue (log2 FC = −0.650, t-test p < 0.001).
This table shows molecular features associated with SLC17A1 in patient tissues and cancer cell lines. In patient samples, SLC17A1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC17A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
